Published in J Biol Chem on December 09, 2011
miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Mol Cancer (2014) 1.05
Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease. Int J Med Sci (2013) 0.83
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
Immunity, inflammation, and cancer. Cell (2010) 28.27
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Res (2003) 6.86
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature (1997) 6.53
GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res (2003) 5.90
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell (2008) 3.04
The immune reaction as a stimulator of tumor growth. Science (1972) 2.63
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2001) 2.08
Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci U S A (2008) 2.05
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery (1999) 1.94
Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res (2011) 1.90
RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev (2005) 1.82
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res (2010) 1.78
Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem (2006) 1.72
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem (1998) 1.64
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res (2006) 1.62
Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem (2000) 1.52
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene (2003) 1.35
Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg (2001) 1.35
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf) (2004) 1.29
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res (2004) 1.19
In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res (1993) 1.19
TRAF-mediated TNFR-family signaling. Curr Protoc Immunol (2009) 1.19
Assembly and regulation of the CD40 receptor complex in human B cells. J Exp Med (1997) 1.17
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene (2004) 1.14
Roles of TRAF6 in CD40 signaling. Immunol Res (2007) 1.08
Hashimoto's thyroiditis and carcinoma of the thyroid gland. Int Surg (1986) 1.08
Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene (2003) 1.06
Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol (2004) 1.05
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer (2005) 1.04
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res (2001) 1.00
Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res (2001) 0.99
Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene (1998) 0.98
The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery (1985) 0.97
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res (2007) 0.96
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med (2010) 0.94
The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem (2010) 0.93
Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab (2010) 0.92
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. J Biol Chem (2006) 0.90
Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem (2004) 0.89
Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics (1997) 0.86
Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice. Oncogene (2001) 0.86
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery (2008) 0.85
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br J Cancer (2001) 0.85
Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene (2004) 0.83
Clinical and biological relationship between chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Oncol Res (2009) 0.82
Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. Mol Endocrinol (2004) 0.82
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Recent Results Cancer Res (1998) 0.82
Antitumor actions of interferon-gamma and interleukin-1 beta on human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab (1995) 0.82
The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK. Oncogene (2010) 0.81
Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Hum Pathol (2008) 0.81
A thyroid tumor-specific antigen formed by the fusion of two self proteins. J Immunol (2003) 0.80
Expression of monocyte chemoattractant protein-1 mRNA and protein in cultured human thyrocytes. FEBS Lett (1996) 0.80
Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways. J Biol Chem (2003) 0.79
Interleukin-6 and transforming growth factor-beta regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating factors in human thyroid follicular cells. Life Sci (1999) 0.78
Production of granulocyte/macrophage and macrophage colony-stimulating factors by human thyrocytes in culture. Biochem Biophys Res Commun (1997) 0.76
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol (2005) 1.41
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood (2003) 1.18
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene (2004) 1.14
Human T-cell responses to vaccinia virus envelope proteins. J Virol (2006) 1.14
Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol (2002) 1.13
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A (2012) 1.09
Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. J Immunol (2003) 1.08
Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol (2011) 1.07
Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene (2003) 1.06
Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol (2004) 1.05
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
Epitopes derived by incidental translational frameshifting give rise to a protective CTL response. J Immunol (2006) 0.99
Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology (2005) 0.99
Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope (2002) 0.98
Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin. J Immunol (2004) 0.98
Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomark Med (2007) 0.95
The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J Immunol (2005) 0.95
Enforced expression of Spi-B reverses T lineage commitment and blocks beta-selection. J Immunol (2005) 0.95
Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol (2009) 0.90
Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin. J Immunol (2010) 0.90
Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope. J Immunol (2006) 0.90
Hydrophobicity as a driver of MHC class I antigen processing. EMBO J (2011) 0.84
Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J Immunol (2002) 0.84
Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity. J Virol (2012) 0.84
Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene (2004) 0.83
Analysis of expansion of myeloid progenitors in mice to identify leukemic susceptibility genes. Mamm Genome (2006) 0.83
Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation. J Immunol (2011) 0.83
Oncogenic inflammation and autoimmune disease. Autoimmun Rev (2006) 0.82
Immunogenicity of cytopathic and noncytopathic viral vectors. J Virol (2006) 0.81
Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR. Proc Natl Acad Sci U S A (2014) 0.80
A thyroid tumor-specific antigen formed by the fusion of two self proteins. J Immunol (2003) 0.80
Vaccinia virus as a tool for immunologic studies. Methods Mol Biol (2004) 0.80
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocr Relat Cancer (2009) 0.78
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas. Eur Arch Otorhinolaryngol (2004) 0.78
Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J Immunol (2008) 0.78
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clin Transl Sci (2008) 0.78
A novel transgenic line of mice exhibiting autosomal recessive male-specific lethality and non-alcoholic fatty liver disease. Hum Mol Genet (2002) 0.77
MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2. J Virol (2014) 0.76
Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor. J Inflamm (Lond) (2008) 0.76
Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy. Immunology (2014) 0.75
Recombinant poxviruses: versatile tools for immunological assays. Methods Mol Biol (2013) 0.75
Antigen processing and presentation. Cancer Treat Res (2005) 0.75